{"organizations": [], "uuid": "7042b92d1aff107337454c64fb0daa7736bcbf26", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180212.html", "section_title": "Archive News &amp; Video for Monday, 12 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-richter-sees-over-50-pct-esmya-sal/brief-richter-sees-over-50-pct-esmya-sales-fall-in-2018-ceo-idUSL8N1Q21K8", "country": "US", "domain_rank": 408, "title": "BRIEF-Richter sees over 50 pct Esmya sales fall in 2018 -CEO", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.272, "site_type": "news", "published": "2018-02-12T16:46:00.000+02:00", "replies_count": 0, "uuid": "7042b92d1aff107337454c64fb0daa7736bcbf26"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-richter-sees-over-50-pct-esmya-sal/brief-richter-sees-over-50-pct-esmya-sales-fall-in-2018-ceo-idUSL8N1Q21K8", "ord_in_thread": 0, "title": "BRIEF-Richter sees over 50 pct Esmya sales fall in 2018 -CEO", "locations": [], "entities": {"persons": [{"name": "gabor orban", "sentiment": "negative"}, {"name": "marton dunai", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "esmya", "sentiment": "none"}], "organizations": [{"name": "esmya", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "richter gedeon vegyeszeti gyar nyrt", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 12 (Reuters) - Richter Gedeon Vegyeszeti Gyar Nyrt CEO Gabor Orban tells press conference:\n* EXPECTS MORE THAN 50 PERCENT SALES DECLINE OF ITS UTERINE FIBROID MEDICINE ESMYA IN 2018\n* RICHTER AIMS TO COOPERATE FULLY WITH EUROPEAN REGULATORS IN PROBE OF ESMYA, NOT CONSIDERING ANY LEGAL COUNTERSTEPS AT THIS POINT\n* ESMYA GLOBAL RIGHTS LISTED AMONG COMPANYâ€˜S ASSETS, WILL BE REVALUED DOWNWARDS AND REFLECTED IN AUDITED BALANCE SHEET TO BE PUBLISHED LATER\n* ESMYA PROBE MIGHT AFFECT COMPANY VALUE THROUGH OUTLOOK OF U.S. REGULATORY APPROVAL PROCESS, LONG-TERM REVENUE AND EARNINGS OUTLOOK Further company coverage: (Reporting by Marton Dunai)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-12T16:46:00.000+02:00", "crawled": "2018-02-13T16:00:37.000+02:00", "highlightTitle": ""}